(4-溴-2-甲酰基苯氧基)乙酸甲酯 | 24581-99-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-溴-2-甲酰基苯氧基)乙酸甲酯
• 中文别名: 2-(4-溴-2-甲烷酰基-苯氧基)乙酸甲酯；2-(4-溴-2-甲酰苯氧基)乙酸甲酯；2-(4-溴-2-甲酰基苯氧基)乙酸甲酯
• 英文名称: methyl (4-bromo-2-formylphenoxy)acetate
• 英文别名: methyl 2-(4-bromo-2-formylphenoxy)acetate
• CAS: 24581-99-5
• 化学式: C₁₀H₉BrO₄
• mdl: MFCD02629616
• 分子量: 273.083
• InChiKey: BGCBNZCJIJRUAY-UHFFFAOYSA-N

物化性质

• 沸点：
  358.1±27.0 °C(Predicted)
• 密度：
  1.536±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  (4-溴-2-甲酰基苯氧基)乙酸甲酯 在 盐酸 、 copper(l) iodide 、 sodium methylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.25h， 生成 5-氰基苯并呋喃-2-羧酸甲酯
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k
• 作为产物：
  描述：

  溴乙酸乙酯 、 5-溴水杨醛 在 potassium carbonate 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 以100%的产率得到(4-溴-2-甲酰基苯氧基)乙酸甲酯
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k

文献信息

• Morita-Baylis-Hillman Route to Dimethyl 2,3-Dihydrobenzo[b]oxepine-2,4-dicarboxylates and Methyl 2-(2-Carbomethoxybenzo[b]furan-3-yl)propanoates from Salicylaldehydes
  作者：Sang-Hyun Ahn、Seung-Soon Jang、Young-Keun Kim、Kee-Jung Lee

  DOI：10.5012/bkcs.2012.33.1.233

  日期：2012.1.20

  A new synthetic method for dimethyl 2,3-dihydrobenzo[b]oxepine-2,4-dicarboxylates and methyl 2-(2-carbomethoxybenzo[b]furan-3-yl)propanoates by an intramolecular conjugate displacement reaction or an $S_N2$ reaction of acetates of Morita-Baylis-Hillman adducts of methyl (2-formylphenoxy)acetates has been described.

  描述了一种新的合成方法，通过分子内共轭取代反应或$S_N2$反应，利用甲基（2-甲醛苯氧基）乙酸酯的Morita-Baylis-Hillman加成物的乙酸酯，制备了二甲基2,3-二氢苯并[b]氧杂环庚烯-2,4-二羧酸酯和甲基2-(2-羧甲基苯并[b]呋喃-3-基)丙酸酯。
• Pyridoxal phosphate. II. Benzene analogs. 2-Formylphenoxyacetic acids as potential antimetabolites of pyridoxal phosphate
  作者：Theodore L. Hullar、D. L. Failla

  DOI：10.1021/jm00303a018

  日期：1969.5
• Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists
  作者：Daniel J. Sall、Ann E. Arfsten、Jolie A. Bastian、Michael L. Denney、Cathy S. Harms、Jefferson R. McCowan、John M. Morin,、Jack W. Rose、Robert M. Scarborough、Mark S. Smyth、Suzane L. Um、Barbara G. Utterback、Robert T. Vasileff、James H. Wikel、Virginia L. Wyss、Joseph A. Jakubowski

  DOI：10.1021/jm970020k

  日期：1997.8.1

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.